What is Shandong Weigao Group Medical Polymer Co ROE %?
Shandong Weigao Group Medical Polymer CoSHWGY +6.90%70 ROE % is 5.06% as of Dec. 2025, which is 55% below its 10-year median of 11.15. GuruFocus rates SHWGY with a GF Score™ of 70/100 and a GF Value™ of $2.98 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Shandong Weigao Group Medical Polymer Co ranks better than 63.7% on this metric.
SHWGY's ROE % is ranked better than 63.7% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs SHWGY: 6.78
Shandong Weigao Group Medical Polymer Co (OTCPK:SHWGY) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Shandong Weigao Group Medical Polymer Co ROE % Related Terms
Shandong Weigao Group Medical Polymer Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Group Medical Polymer Co ROE % Chart
Shandong Weigao Group Medical Polymer Co Annual Data
For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Group Medical Polymer Co ROE % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Shandong Weigao Group Medical Polymer Co (SHWGY) has a ROE % of 5.06% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. This is 55% below median its historical median of 11.15. Over the past decade, Shandong Weigao Group Medical Polymer Co's ROE % has ranged from 6.78 to 14.08. According to the industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #290 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 36.3%.
Is Shandong Weigao Group Medical Polymer Co's ROE % too high?
Shandong Weigao Group Medical Polymer Co's current ROE % of 5.06% is 55% below median its 10-year median of 11.15. Over the past 10 years, this metric has ranged from a low of 6.78 to a high of 14.08. The Medical Devices & Instruments industry median ROE % is 2.42. Shandong Weigao Group Medical Polymer Co's value of 5.06% is 109.1% above this industry median. Based on the distribution chart, Shandong Weigao Group Medical Polymer Co ranks #290 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Group Medical Polymer Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Group Medical Polymer Co's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Group Medical Polymer Co ranks #290 out of 799 companies for ROE %. This puts Shandong Weigao Group Medical Polymer Co in the upper half of its industry. The industry median ROE % is 2.42. Shandong Weigao Group Medical Polymer Co's value of 5.06% is 109.1% above this benchmark. Historically, Shandong Weigao Group Medical Polymer Co's own ROE % has ranged from 6.78 to 14.08 over the past decade. While the company's 10-year median is 11.15 vs. the industry median of 2.42, Shandong Weigao Group Medical Polymer Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Group Medical Polymer Co's current ROE % of 5.06% is 109.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shandong Weigao Group Medical Polymer Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Group Medical Polymer Co's current ROE % is 5.06%, which is 55% below median its own 10-year median of 11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Group Medical Polymer Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co (SHWGY) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.98, compared to a current price of $1.60 — trading 46.5% below its estimated fair value. The current ROE % is 5.06%, which is 55% below median its 10-year median of 11.15 and 109.1% above the Medical Devices & Instruments industry median of 2.42. Shandong Weigao Group Medical Polymer Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shandong Weigao Group Medical Polymer Co (SHWGY), the current ROE % is 5.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Weigao Group Medical Polymer Co (SHWGY) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Weigao Group Medical Polymer Co stock appears to be undervalued.
The current stock price of $1.60 is trading 46.5% below its estimated GF Value™ of $2.98.
GuruFocus considers Shandong Weigao Group Medical Polymer Co to be Significantly Undervalued.
Key valuation signals for SHWGY:
ROE %: 5.06% (55% below median its 10-year median of 11.15)
GF Value™: $2.98 vs. price of $1.60 (46.5% below fair value)
Industry Position: 109.1% above the Medical Devices & Instruments median (#290 of 799)
No single metric tells the full story. See the SHWGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Weigao Group Medical Polymer Co Business Description
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.
70GF Score
Get the complete analysis for SHWGY
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHWGY has been successfully added to your 
